11 results
To make an efficacy evaluation of Gadolineum Ethoxybenzyl (Gd-EOB) DTPA-enhanced MR-imaging (Gadoxetic acid, Primovist, Bayer Schering Pharma, Berlin) and Respiratory Triggered Diffusion Weighted Imaging (DWI) for the detection and characterization…
To measure the PK of ARA290 when given in de SQ form
To assess the analgesic effect of ARA290 in chronic pain patients
To show differences in uptake of Primovist between FNHs and hepatocellular adenomas on CT.
The primary objective of Part 1 is the primary objective of the entire study.Part 1The primary objective of Part 1 is:* To evaluate the effect of ZX008 0.8 mg/kg/day versus placebo as adjunctive therapy for the treatment of uncontrolled seizures in…
The primary efficacy objectives of this two-cohort study are:o To demonstrate that ZX008 is superior to placebo as adjunctive therapy in the treatment of symptoms of Dravet syndrome in children and young adults based on change in the frequency of…
In this study we will assess the effect of ARA290 on nerve damage by taking 4 skin bipsies during treatment.
To measure the plasma conc. of ARA 290 in healthy volunteers
Treatment strategy in early HCC aims at the local removal of the tumor and represents a potentially curative treatment option (resection, liver transplantation, PEI, RFA, BT). Patients in intermediate and advanced stage of HCC receive treatment with…
ARA290 is a new drug against neuropathic pain and was succesfully tested in previous studies on patients with neuropathic pain due to diabetes and sarcoidosis. The current study involves sarcoidosis patients with pain due to neuropathy. The purpose…
To prospectively assess the potential effect of repeated exposure to either a linear or amacrocyclic gadolinium-based contrast agent (GBCA) on change from baseline to Year 5 inmotor and cognitive function among neurologically normal adults in…